Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 4Other hematologic neoplasm 2Plasma cell 1Myeloid 1Lymphoid 1Genitourinary 1CNS 1

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia 1

Interventions

Cyclophosphamide 414Cytarabine 336fludarabine phosphate 231Rituximab 206Methotrexate 198fludarabine 196venetoclax 174Azacitidine 174Busulfan 169Filgrastim 145Whole-Body Irradiation 143Mycophenolic Acid 143Peripheral Blood Stem Cell Transplantation 141Tacrolimus 138Etoposide 130Vincristine 112Melphalan 110Dexamethasone 109Cyclosporine 102Granulocyte Colony-Stimulating Factor 100Imatinib Mesylate 94Antilymphocyte Serum 91Daunorubicin 90Radiotherapy 84Decitabine 83Dasatinib 76Lenalidomide 75Doxorubicin 70Prednisone 68Idarubicin 68

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Protein Subunit Vaccines × Other hematologic neoplasm × Clear all
NCT02802943 2022-11-28

iVAC-CLL01: Patient-individualized Peptide Vaccination After First Line Therapy of CLL

University Hospital Tuebingen

Phase 2 Completed
56 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT00415857 2018-08-21

Proteinase 3 PR1 Peptide Mixed With Montanide ISA-51 VG Adjuvant and Administered With GM-CSF and PEG-INTRON(R)

M.D. Anderson Cancer Center

Phase 2 Terminated
5 enrolled 3 charts
MyeloidOther hematologic neoplasm

Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡